Skip to Content
Merck
All Photos(1)

Documents

719900

Sigma-Aldrich

Resomer® RG 504 H, Poly(D,L-lactide-co-glycolide)

acid terminated, lactide:glycolide 50:50, Mw 38,000-54,000

Synonym(s):

PLGA

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
26780-50-7
UNSPSC Code:
12162002
NACRES:
NA.23

form

amorphous

feed ratio

lactide:glycolide 50:50

mol wt

Mw 38,000-54,000

degradation timeframe

<3 months

viscosity

0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 46-50 °C

storage temp.

2-8°C

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

Application

Resomer® RG 504 H, Poly(D, L-Lactide-co-Glycolide) can be used to fabricate a biodegradable hemostyptic device for safe and locally controlled release of thrombin which promotes local blood clot formation.

It can be used to preparepolymer nanospheres for encapsulating CuO, to form stimuli-responsivemultifunctional nanocarriers.

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

related product

Product No.
Description
Pricing

911593

NanoFabTx™ microfluidic - nano, device kit for synthesis of 100-200 nm nanoparticles and liposomes

911860

NanoFabTx™ microfluidic - micro, device kit for synthesis of 1-5 μm particles

911879

NanoFabTx™ microfluidic - micro, device kit for synthesis of 10-30 μm particles

909637

NanoFabTx™ PLGA-nano, for synthesis of 100 and 200 nm particles

912212

NanoFabTx™ PLGA-micro, for synthesis of 10-30 um particles

912220

NanoFabTx™ PLGA-micro, for synthesis of 1-5 μm particles

920436

NanoFabTx™ PEG-PLA drug formulation screening kit, for synthesis of PEGylated nanoparticles

915408

NanoFabTx™ PEGylated nanoparticle formulation screening kit

917796

NanoFabTx™ PEG-PLGA drug formulation screening kit, for synthesis of PEGylated nanoparticles

918881

NanoFabTx™ PEG-PCL drug formulation screening kit, for synthesis of PEGylated nanoparticles

918075

NanoFabTx™ PLA-nano, for synthesis of 100 and 200 nm particles

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Niranjan G Kotla et al.
Nanomaterials (Basel, Switzerland), 9(9) (2019-09-05)
There is a pressing clinical need for advanced colon-specific local drug delivery systems that can provide major advantages in treating diseases associated with the colon, such as inflammatory bowel disease (IBD) and colon cancer. A precise colon targeted drug delivery
Hossein Kamali et al.
Materials science & engineering. C, Materials for biological applications, 96, 561-575 (2019-01-05)
An in situ forming gel (ISFG) of buprenorphine (BP) was prepared using PLGA-PEG-PLGA (triblock) and N‑methyl‑2‑pyrrolidone as solvent for decreasing the initial burst release. Supercritical CO2 method was used for ring opening polymerization of triblock. The optimum formulation of ISFG
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
Igor Jeroukhimov et al.
Journal of the American College of Surgeons, 218(1), 102-107 (2013-11-12)
Chronic pain after inguinal hernia repair occurs in 16% to 62% of patients. The underlying mechanism probably involves sensory nerve damage and abnormal healing that might be influenced by the materials chosen for the procedure. We hypothesize that nonabsorbable sutures
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service